Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

LOPERAMIDE HCL

All products: not a benefit

Other products in the same Health Canada class (A07DA) — coverage varies; not interchangeable

  • Atropine + diphenoxylate (Lomotil): limited Use 110, 111, 112, 113, 114, 115, 224

Imodium · DIN 00860743 · 2mg · Caplet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1999-06-16 — choose a marketed DIN from the same-category list.Discontinued 1999-06-16 · checked 2026-09-20
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1999-06-16 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 1999-06-16 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 110, 111, 112, 113, 114, 115, 224
Coverage limit: For the treatment of diarrhea associated with: Reason for Use code 110 An ileostomy or a colostomy;. Coverage limit: LU Authorization Period: 1 year Reason for Use code 111 Bowel resection, including short bowel syndrome; Coverage limit: LU Authorization Period: 1 year Reason for Use code 112 Inflammatory Bowel Diseases, i.e. Crohn's Disease and Ulcerative Colitis; Coverage limit: LU Authorization Period: 1 year Reason for Use code 113 Cancer, including chemotherapy or radiation therapy; Coverage limit: LU Authorization Period: 1 year Reason for Use code 114 HIV/AIDS; Coverage limit: LU Authorization Period: 1 year Reason for Use code 115 Acute diarrhea in patients in congregated housing, i.e. Long Term Care Facilities (LTCF), or for patients receiving Home Care; Coverage limit: LU Authorization Period: 1 year Reason for Use code 224 Fecal incontinence. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Imodium · DIN 00860743 Manufacturer: Janssen Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 1999-06-16 · brand IMODIUM CAPLETS 2MG · ATC A07DA03 LOPERAMIDE · form Tablet · route Oral · ingredients LOPERAMIDE HYDROCHLORIDE 2 MG/TAB · company Janssen pharmaceutica, division of janssen-ortho inc. · schedule Non-prescription drugs
Check this DIN again · Health Canada product record

Imodium: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10543 · Verify on the e-Formulary ↗ (DIN 00860743)

Source record
DIN 00860743: Imodium Raw flags: notABenefit=Y, sec3=Y Item: 560800015; group id 647; item number 1626; lccId 00096; manufacturer id JAN Source form: Caplet; strength: 2mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00860743 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10543
Interchangeable products
Apo-Loperamide · DIN 02212005 · $0.0952 PMS-Loperamide · DIN 02228351 · $0.0952 Teva-Loperamide · DIN 02132591 · $0.0952
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 1999-06-16 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (56:08 Antidiarrhea Agents) and how they are covered

Matched class: 56:08 Antidiarrhea Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. No displayed product is listed as a general benefit in this extract. Check its listing requirements below. 56:08 Antidiarrhea Agents

DIPHENOXYLATE HYDROCHLORIDE & ATROPINE SULFATE

· 1 products · Limited Use, codes 110, 111, 112, 113, 114, 115, 224 · strengths: 2.5mg & 0.025mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 56:08
Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:12 Cathartics, 56:16 Digestants, 56:22 Antiemetics and Antinauseants, 56:40 Miscellaneous G.I. Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS TEVA-LOPERAMIDE (Loperamide Hydrochloride) is indicated:  as an adjunct to rehydration therapy for the symptomatic control of acute non-specific diarrhea  for chronic diarrhea associated with inflammatory bowel disease  for reducing the volume of discharge for ileostomies, colostomies and other intestinal resections Treatment of diarrhea with TEVA-LOPERAMIDE is only symptomatic. Whenever an underlying etiology can be determined, specific treatment should be given when appropriate (or when indicated). 1.1 Pediatrics Pediatrics (2 to 12 years of age): Loperamide should be used in children only on the advice of a physician. TEVA-LOPERAMIDE tablets are not suited for children under 6 years of age. 1.2 Geriatrics Geriatrics (>65 years of age): No dose adjustments are required for the elderly. https://pdf.hres.ca/dpd_pm/00080964.PDF PM date: December 23, 2016 Source product: TEVA-LOPERAMIDE; DIN 02132591; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Imodium: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026